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SUMMARY
Hadad R, Jensen JS, Westh H, Grønbæk I, Schwartz LJ, Nielsen L, Vang TM, Nielsen R, 
Weinreich LS, Skov MN, Olsen M, Møller JK, Kolmos B, Unemo M, Hoffmann S. A Chlamydia 
trachomatis 23S rRNA G1523A variant escaping detection in the Aptima Combo 2 assay 
(Hologic) was widespread across Denmark in July-September 2019
Chlamydia trachomatis infection is the most common bacterial sexually transmitted infection 
globally, and nucleic acid amplification tests (NAATs) are recommended for highly sensitive and 
specific diagnosis. In early 2019, the Finnish new variant of Chlamydia trachomatis (FI-nvCT) 
was identified. The FI-nvCT has a C1515T mutation in the 23S rRNA gene, making it escaping 
detection in the Aptima Combo 2 (AC2; Hologic) NAAT, and the FI-nvCT has been subsequently 
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and other AC2 diagnostic-escape CT mutants in July-September 2019 in Denmark. The FI-nvCT 
was present but rare in Denmark. However, another AC2 diagnostic-escape CT mutant (with a 23S 
rRNA G1523A mutation) was found to be widespread across Denmark, accounting for 95% 
(76/80) of AC2 diagnostic-escape nvCT samples from five Danish CT-diagnostic laboratories. 
This nvCT-G1523A has previously only been detected in one single sample in the United 
Kingdom and Norway, respectively. It is vital to monitor the continued stability of the NAAT 
targets in local, national and international settings and monitor as well as appropriately analyse 
incidence, unexplained shifts in diagnostics rates, and/or annual collections of samples diagnosed 
as negative/equivocal using NAATs with different target(s). Furthermore, diagnostic CT NAATs 
with dual target sequences are crucial and fortunately, an updated Hologic AC2 assay including 
one additional target sequence is in advanced development. 
Key words: Chlamydia trachomatis, FI-nvCT, New variant, Aptima Combo 2 assay, 23S rRNA, 
C1515T, G1523A, Denmark
Magnus Unemo, WHO Collaborating Centre for Gonorrhoea and other STIs, Department of 
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INTRODUCTION
Chlamydia trachomatis infection is the most common bacterial sexually transmitted infection 
globally (1), and nucleic acid amplification tests (NAATs) are recommended for highly sensitive 
and specific diagnosis (2,3). In early 2019, the Finnish new variant of Chlamydia trachomatis (FI-
nvCT) was identified (4,5). The FI-nvCT has a C1515T mutation in the CT 23S rRNA gene, 
making it escaping detection in the Aptima Combo 2 (AC2; Hologic Inc., San Diego, CA, USA) 
NAAT that targets CT 23S rRNA (4-9). The FI-nvCT has been subsequently reported in Sweden 
(6) and Norway (7). Two additional very rare AC2 diagnostic-escape nvCTs were described in 
single specimens in Norway (7) and the United Kingdom (8). As the FI-nvCT, these two rare 
diagnostic-escape nvCTs also had a single nucleotide polymorphism (SNP) in the CT probe 
detection 23S rRNA sequence of AC2, that is, 23S rRNA C1514T or G1523A (7,8). The AC2 
detection is measured in relative light units (RLUs) and the 23S rRNA mutations in these nvCTs 
result in low CT RLU values, mostly 15-99, that are interpreted as negative or equivocal in AC2 
(4-9). The Aptima C. trachomatis NAAT (ACT; Hologic Inc.), which targets CT 16S rRNA, 
detects all these diagnostic-escape nvCTs, and reflex testing of AC2 samples with CT RLU values 
of 15-99 using ACT was implemented in May-June 2019 in many European countries (9,10).  
Considering the spread of particularly the FI-nvCT in Finland (4,5), Sweden (6) and Norway 
(7); the close geographic proximity and frequent travelling between the Nordic countries; and the 
rapid risk assessment published by the European Centre for Disease Prevention and Control 
(ECDC) on 17 June 2019 (10), it was urgent to appropriately investigate if the FI-nvCT and/or 
additional AC2 diagnostic-escape nvCTs were spreading also in Denmark. In Denmark, with over 
5.8 million inhabitants, the majority (62% in 2019) of CT samples are analysed using AC2 on 
Panther instruments (Hologic Inc.).    
MATERIALS AND METHODS
The numbers of mandatorily reported CT cases in Denmark in 2018 and 2019 were obtained at the 
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five CT-diagnostic clinical microbiology laboratories across Denmark, i.e. in Hvidovre, Herlev, 
Odense, Vejle and Aalborg (all AC2 laboratories in Denmark and together responsible for 62% of 
the CT diagnostic testing in 2019), from 1 July to 30 September 2019 were assessed. Samples with 
AC2 CT RLU values of 15-97 were reflex tested using the ACT. AC2 and ACT were performed in 
accordance with the instructions from the manufacturer (Hologic Inc., San Diego, CA, USA). 
Confirmation of AC2 diagnostic-escape nvCTs (one sample per patient) was performed by 
sequencing of the V2 region of the 23S rRNA gene at the WHO Collaborating Centre for 
Gonorrhoea and other STIs, Sweden, as described previously (5).
RESULTS
Diagnostics and incidence of Chlamydia trachomatis in Denmark
The number of CT cases in Denmark in 2019 compared to 2018 was similar for each month until 
ACT reflex testing of AC2 samples with CT RLU values of 15-99, in accordance with the ECDC 
rapid risk assessment (10), was initiated in mid- to late-June 2019 (FIG. 1). After ACT reflex 
testing started, an increase in the number of CT positive samples was seen compared to the 
corresponding months in 2018, i.e. an increase by 461 CT positive cases in July 2019, 486 cases in 
August and 364 cases in September (FIG. 1). However, the significance of these findings is not 
clear due to the fluctuations of number of positive samples, particularly in different months and 
seasons, such as summer, and over the years. 
Possible cases of AC2 diagnostic-escape nvCTs in Denmark 
Consecutive clinical AC2 specimens obtained at five CT-diagnostic clinical microbiology 
laboratories across Denmark, i.e. in Hvidovre, Herlev, Odense, Vejle and Aalborg, from 1 July to 
30 September 2019 were assessed. During these months, 66552 samples (Hvidovre: 34737, 
Herlev: 12717, Odense: 6850, Vejle: 4184, Aalborg: 8064) were examined and 6117 samples 
(9.2%) were positive for CT in AC2 (Hvidovre: 2726, Herlev: 1210, Odense: 687, Vejle: 504, 
Aalborg: 990). In total, 707 (1.1%) samples with AC2 CT RLU values of 15-97 were reflex tested 
using the ACT. Of these samples (n=707), 204 (28.9%) were positive in ACT (RLUs 94-8891) 
(FIG. 2) and accordingly possible cases of AC2 diagnostic-escape nvCTs (Hvidovre: 107, Herlev: 
35, Odense: 37, Vejle: 6, Aalborg: 19). 
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In total, samples from 150 of the above mentioned possible cases of AC2 diagnostic-escape nvCTs 
(Hvidovre: 85, Herlev: 20, Odense: 28, Vejle: 4, Aalborg: 13) were available for sequencing (the 
vast majority from July-August 2019). Eighty (53.3%) of these samples contained an nvCT with a 
SNP in the AC2 CT probe detection sequence of the 23S rRNA gene (12 (8.0%) contained CT 
wild type and 58 (38.7%) had too low bacterial load for sequencing). Notably, nine (6%) of the 
150 possible cases of AC2 diagnostic-escape nvCTs were also positive for Neisseria gonorrhoeae. 
Of the 80 AC2 diagnostic-escape nvCT samples, 95% (n=76) contained nvCT with the G1523A 
SNP in the 23S rRNA gene (RLUs: 16-86), 2.5% (n=2) 23S rRNA C1514T (RLUs: 17 and 25), 
and 2.5% (n=2) 23S rRNA C1515T (RLUs: 21 and 26), that is, the FI-nvCT. The AC2 diagnostic-
escape nvCT G1523A was widely spread across Denmark and detected in Hvidovre (n=43), 
Herlev (n=15), Odense (n=7), Vejle (n=4), and Aalborg (n=7). The nvCT C1514T and the FI-
nvCT was found in one sample each in Hvidovre and Odense, respectively. Gender distribution 
was 97 females, 50 males and three unknown. No information regarding the age, sexual 
orientation or recent travel of the patients was available for the present study.  
DISCUSSION
In the present study, we identified in Denmark all three previously described AC2 diagnostic-
escape nvCTs causing false-negative or equivocal AC2 results (4-8). The FI-nvCT was initially 
published in late-May 2019 in Finland (4) and the prevalence of FI-nvCT appeared to be relatively 
high in particular in South-West Finland (4,5). FI-nvCT was subsequently reported to be present in 
Sweden (6) and widely spread in Norway (7). Two additional AC2 diagnostic-escape nvCTs, with 
23S rRNA C1514T or G1523A gene mutation, were also found in one sample each in Norway (7) 
and the United Kingdom (8), respectively. Already in mid-June 2019, recommendations to ACT 
reflex test all specimens with AC2 CT RLU values of 15-99 (possible AC2 diagnostic-escape 
nvCT) were published (9,10). Most worryingly, in Denmark 0.3% of all samples and 3.3% of all 
CT positive samples examined with AC2 from July to September 2019 were possible cases of an 
AC2 diagnostic-escape nvCT. Furthermore, 95% (n=76) of the confirmed AC2 diagnostic-escape 
nvCT samples, corresponding to 0.2% of all examined AC2 samples or 1.9% of all true AC2 CT 
positive samples (likely underestimated because 39% of samples could not be sequenced) from 
July to August 2019, contained the 23S rRNA G1523A nvCT. Surprisingly, this widely spread 
nvCT-1523A has still not been detected in the neighbouring country Sweden (6,unpublished) and 
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Finland (4,5) and Norway (7), and not exceedingly rare in Sweden (6,unpublished). This indicates 
that the spread of CT strains between Denmark and the additional Nordic countries is more limited 
than anticipated, which was also indicated as one of the contributing factors more than 10 years 
ago when the Swedish nvCT was widely spreading in Sweden but very rare in Denmark (11-13). 
An Aptima-based FI-nvCT specific assay has now been developed and will be used in a pan-
European surveillance study (9). Based on the present results from Denmark, it is important to not 
only use the Aptima-based FI-nvCT specific assay in the pan-European study, but additionally 
perform 23S rRNA gene sequencing on AC2/ACT discordant samples from countries where other 
diagnostic-escape CT variants are widespread, such as in Denmark, where the proportion of 
AC2/ACT discordant samples negative in the FI-nvCT specific assay is high, or where the 
distribution of diagnostic-escape CT variants or AC2/ACT discordant samples is completely 
unknown. The results of the present study show that the ACT reflex testing currently 
recommended for AC2 samples with CT RLUs of 15-99 should be continuously performed (9,10), 
and the CT RLU values caused by the nvCT-1523A monitored, i.e. to ensure that the RLU≥15 cut-
off captures also all nvCT-1523A samples. Ultimately, a validated and quality assured revised 
version of AC2 that detects all the diagnostic-escape CT variants is very important, and such 
NAAT is fortunately in advanced development (14). 
Whole genome sequencing of the different AC2 diagnostic-escape nvCTs is in progress and 
this work will contribute to the understanding on how CT is evolving including the emergence, 
clonality, spread, and fitness advantages/disadvantages of these nvCTs. The presence of several 
different reported AC2 diagnostic-escape nvCTs illustrates the vulnerability of using a single 
target for detection of an infectious agent with nucleic acid amplification tests (NAATs). This was 
seen already with the experience of the Swedish nvCT initially detected in 2006 in Sweden where 
a deletion in the cryptic plasmid that included the target sequence for the Roche and Abbott CT 
NAATs led to diagnostic escape (11-13). Previous genomic, phenotypic and epidemiological 
studies on the Swedish nvCT did not reveal any altered biological fitness and instead showed that 
the rapid spread was most likely mainly due to the advantage of a strong diagnostic selection, 
introduction in a high-frequency transmitting population, and the lack of subsequent tracing and 
treatment of sexual contacts (11). 
In conclusion, it is vital to monitor the continued stability of the NAAT targets in local, 
national and international settings and monitor as well as appropriately analyse incidence, 
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negative/equivocal using NAATs with different target(s). Furthermore, diagnostic CT NAATs 
with dual target sequences are crucial and fortunately, an updated Hologic AC2 assay including 
one additional target sequence is in advanced development (14). Finally, international and national 
surveillance programmes capturing NAAT diagnostic-escape variants for CT and other infectious 
agents are imperative.
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Figure legends
FIG 1. Number of Chlamydia trachomatis (CT) cases reported in Denmark from January to 
September 2018 and 2019, respectively. Reflex testing using the Aptima CT assay started in mid-
June 2019, which is indicated by a black line. 
FIG 2. Number of samples tested positive for Chlamydia trachomatis (CT) in Aptima Combo 2 
assay (AC2; black), samples that qualified for reflex testing by Aptima CT assay (ACT; dark 
grey), and samples that tested positive in ACT (light grey). The number of samples examined in 
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